Interesting conclusion on superiority of CRT over ICD
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Pharmacology
November 6, 2023
An elegant and surprisingly easily read cohort study of mechanical destruction of platelets in ECMO circuits that parallels what we already know in pumps for full cardiopulmonary bypass. The authors propose a biomarker as a target for thrombotic modulation .
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
May 26, 2022
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
April 5, 2022
A brief but comprehensive editorial on nuances of the links between atrial fibrillation and heart failure, apropos a trial we have commented recently on, by the Johns Hopkins team that develops the calmodulin-dependent protein kinase II inhibitor molecules
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
November 9, 2021
A good-size Terumo-sponsored RCT that is set to impact on decisions to discontinue DAPT early after PCI with absorbable stent, a change that will somehow decrease the surgical risk of bleeding in the event of salvage CABG.
November 1, 2021
An extremely useful and free-access update on a major vascular entity. The 'Areas of Uncertainty' is a particularly useful chapter, discussing the available technology and its current supra-renal limitations and the emerging solutions.
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
September 24, 2021
A comprehensive update on the evidence on the management of acute aortic syndromes, including IMH. Of particular interest is the robust recommendation to bypass non-dedicated aortic centers even to the expense of increased transit time in order to offer management in a Comprehensive Aortic Center (CAC).